Chloroquine phosphate: therapeutic drug for COVID-19
et al., Journal of Southern Medical University, doi:10.12122/j.issn.1673-4254.2020.04.22, Apr 2020
HCQ for COVID-19
1st treatment shown to reduce risk in
March 2020, now with p < 0.00000000001 from 424 studies, used in 59 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
Review of chloroquine phosphate in the treatment of COVID-19. Authors summarize the antiviral potential of chloroquine phosphate, emphasizing its inclusion in China's diagnostic and treatment guidelines for COVID-19. The drug has shown antiviral effects both in vitro and in preliminary clinical trials, with evidence suggesting efficacy in reducing disease progression, improving lung imaging, and promoting viral clearance compared to lopinavir/ritonavir. Chloroquine's mechanism includes altering lysosomal pH to inhibit viral entry and replication and modifying ACE2 glycosylation to disrupt viral-host cell binding. Authors note that chloroquine has a narrow therapeutic window and significant pharmacokinetic variability which raises concerns about toxicity and highlights the need for close monitoring and tailored dosing to minimize adverse effects while ensuring therapeutic efficacy.
1.
Mothae et al., SARS-CoV-2 host-pathogen interactome: insights into more players during pathogenesis, Virology, doi:10.1016/j.virol.2025.110607.
2.
Monsalve et al., NETosis: A key player in autoimmunity, COVID-19, and long COVID, Journal of Translational Autoimmunity, doi:10.1016/j.jtauto.2025.100280.
3.
Xie et al., The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death, Cellular & Molecular Biology Letters, doi:10.1186/s11658-024-00659-6.
4.
Gkioulekas et al., Use of hydroxychloroquine in multidrug protocols for SARS-CoV-2, Tasman Medical Journal, 6:4, tasmanmedicaljournal.com/2024/10/use-of-hydroxychloroquine-in-multidrug-protocols-for-sars-cov-2a/.
5.
Gortler et al., Those Published “17,000 Hydroxychloroquine Deaths” Never Happened, Brownstone Journal, brownstone.org/articles/those-published-17000-hydroxychloroquine-deaths-never-happened/.
6.
Boretti et al., Correct Use of HCQ Did Not Cause Extra Fatalities in COVID-19 Infection, Coronaviruses, doi:10.2174/0126667975327612240902104505.
7.
Gortler (B) et al., Trump’s 63 Million Doses of Hydroxychloroquine Could Have Been Great for America, Brownstone Journal, brownstone.org/articles/trumps-63-million-doses-of-hydroxychloroquine-could-have-been-great-for-america/.
8.
Enyeji et al., Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports, Viral Immunology, doi:10.1089/vim.2024.0034.
9.
Asaba et al., Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity in COVID-19 Infections, Journal of Inflammation Research, doi:10.2147/jir.s474707.
10.
Scheim et al., Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses, Viruses, doi:10.3390/v16040647.
11.
Ali et al., SARS-CoV-2 Syncytium under the Radar: Molecular Insights of the Spike-Induced Syncytia and Potential Strategies to Limit SARS-CoV-2 Replication, Journal of Clinical Medicine, doi:10.3390/jcm12186079.
12.
Brouqui et al., There is no such thing as a Ministry of Truth and why it is important to challenge conventional “wisdom” - A personal view, New Microbes and New Infections, doi:10.1016/j.nmni.2023.101155.
13.
Loo et al., Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections, Pharmaceutical Research, doi:10.1007/s11095-023-03520-1.
14.
Boretti (B), A., Pharmacotherapy for Covid-19 infection in the countries of the Cooperation Council for the Arab States, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2021.08.005.
15.
Vigbedor et al., Review of four major biomolecular target sites for COVID-19 and possible inhibitors as treatment interventions, Journal of Applied Pharmaceutical Science, doi:10.7324/JAPS.2021.110825.
16.
Kaur et al., Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?, Medical Hypotheses, doi:10.1016/j.mehy.2021.110539.
17.
Raoult, D., Rational for meta-analysis and randomized treatment: the COVID-19 example, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.10.012.
18.
Matada et al., A comprehensive review on the biological interest of quinoline and its derivatives, Bioorganic & Medicinal Chemistry, doi:10.1016/j.bmc.2020.115973.
19.
IHU, Natural history and therapeutic options for COVID-19, Expert Review of Clinical Immunology, www.mediterranee-infection.com/wp-content/uploads/2020/09/ERM-2020-0073.R1_Proof_hi.pdf.
20.
Hecel et al., Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?, Pharmaceuticals, 13:9, 228, doi:10.3390/ph13090228.
21.
Li et al., Is hydroxychloroquine beneficial for COVID-19 patients?, Cell Death & Disease volume 11, doi:10.1038/s41419-020-2721-8.
22.
Goldstein, L., Hydroxychloroquine-based COVID-19 Treatment, A Systematic Review of Clinical Evidence and Expert Opinion from Physicians’ Surveys, Preprint, July 7, 2020, wattsupwiththat.com/2020/07/07/hydroxychloroquine-based-covid-19-treatment-a-systematic-review-of-clinical-evidence-and-expert-opinion-from-physicians-surveys/.
23.
Roussel et al., Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences, New Microbes and New Infections, Volume 38
, doi:10.1016/j.nmni.2020.100710.
24.
Mo et al., Chloroquine phosphate: therapeutic drug for COVID-19, Journal of Southern Medical University, doi:10.12122/j.issn.1673-4254.2020.04.22.
25.
Gao et al., Update on Use of Chloroquine/Hydroxychloroquine to Treat Coronavirus Disease 2019 (COVID-19), Biosci Trends, May 21, 2020, 14:2, 156-158, doi:10.5582/bst.2020.03072.
26.
Derwand et al., Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?, Medical Hypotheses, doi:10.1016/j.mehy.2020.109815.
27.
Sahraei et al., Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine, International Journal of Antimicrobial Agents, April 2020, 55:4, doi:10.1016/j.ijantimicag.2020.105945.
28.
Todaro et al., An Effective Treatment for Coronavirus (COVID-19), github.com/covidtrial/info/raw/master/An%20Effective%20Treatment%20for%20Coronavirus%20(COVID-19).pdf.
Mo et al., 22 Apr 2020, peer-reviewed, 2 authors.
体外抗病毒研究 COVID-19疫情发生后， 中国的科学家为寻找有效 的抗病毒药物， 做了大量的体外细胞筛选试验。2020 Chloroquine phosphate: therapeutic drug for COVID-19
doi:10.12122/j.issn.1673-4254.2020.04.22
Since the outbreak of coronavirus disease 2019 (COVID-19) in the late 2019, a variety of antiviral drugs have been used in the first-line clinical trial. The Diagnostic and Treatment Protocol for COVID-19 (Trial Version 6) in China recommends chloroquine phosphate for the first time as an anti-coronavirus trial drug. As a classic drug for treatment of malaria and rheumatism, chloroquine phosphate has been used clinically for more than 80 years, and has also shown good results in the treatment of various viral infections. As the plasma drug concentration varies greatly among different races and individuals and due to its narrow treatment window, chloroquine in likely to accumulate in the body to cause toxicity. Among the treatment regimens recommended for COVID-19, reports concerning the safety of a short-term high-dose chloroquine regimen remain scarce. In this review, the authors summarize the current research findings of chloroquine phosphate in the treatment of COVID-19, and examine the pharmacokinetic characteristics, antiviral therapy, the therapeutic mechanism and safety of chloroquine.
References
Cortegiani, Ingoglia, Ippolito, A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 ［J］, J Crit Care, doi:10.1016/j.jcrc.2020.03.005
Huang, Tang, Pang, Treating COVID-19 with Chloroquine［J］, J Mol Cell Biol, doi:10.1093/jmcb/mjaa014
Moussavi, Ruengweerayut, Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border ［J］, J Mal
Mégarbane, Bloch, Hirt, Blood concentrations are better predictors of chioroquine poisoning severity than plasma concentrations: a prospective study with modeling of the concentration/effect relationships ［J］, Clin Toxicol
Pb, Panchal, Warren, Evaluation of Ebola Virus Inhibitors for Drug Repurposing ［J］, ACS Infect Dis
Riou, Barriot, Rimailho, Treatment of Severe Chloroquine Poisoning ［J］, New Engl J Med
Tang, Ye, Huang, An Overview of Available Antimalarials: Discovery, Mode of Action and Drug Resistance ［J］, Curr Mol Med, doi:10.2174/1566524020666200207123253
Vincent, Bergeron, Benjannet, Chloroquine is a potent inhibitor of SARS coronavirus infection and spread［J］, J Virol
Wang, Cheng, Increasing Host Cellular Receptor-Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV Infection ［J］, bioRxiv, doi:10.1101/2020.02.24.963348
［12 ; ］梁晓竟, 氯喹抗疟研究概况 ［J］, 预防医学情报杂志
［17 ; Al-Bari, Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases［J］, J Antimicrob Chemoth
［19 ; ］routy, Angel, Patel, Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy ［J］, HIV Med
［20 ; ］al-Bari, Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases ［J］, Pharmacol Res Perspect
［21 ; ］savarino, Shytaj, Chloroquine and beyond: exploring antirheumatic drugs to reduce immune hyperactivation in HIV/AIDS ［J］, Retrovirology
［26 ; Schrezenmeier, Dörner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology［J］, Nat Rev Rheumatol
［28 ; ］li R, Qiao, Zhang, Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV ［J］, J Infect, doi:10.1016/j.jinf.2020.02.013
［2］ ; 中心协作组, 广东省科技厅及广东省卫生健康委磷酸氯喹治疗新冠状病毒肺炎多, 中华结 核和呼吸杂志, doi:10.3760/cma.j.issn.1001-0939.2020.0019
［3 ; Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro ［J］, Cell Res
［32 ; Ducharme, Farinotti, Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements ［J］, Clin Pharmacokinet
［4 ; Mackenzie, Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials［J］, Am J Med
［41 ; ］olafuyi, Badhan, Dose Optimization of Chloroquine by Pharmacokinetic Modeling During Pregnancy for the Treatment of Zika Virus Infection ［J］, J Pharm Sci
［42 ; ］taylor Wr, White, Antimalarial drug toxicity: a review［J］, Drug Safety
［44 ; ］kiel, Chloroquine Suicide ［J］, JAMA
［49 ; ］luzzi, Peto, Adverse Effects of Antimalarials［J］, Drug Safety
［5 ; Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies ［J］, Bio Sci Trends
［7 ; Gupta, Agrawal, Ish, Chloroquine in COVID-19: the evidence ［J］, Monaldi Arch Chest Dis, doi:10.4081/monaldi.2020.1290
［8 ; Gbinigie, Frie, Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review ［J］, BJGP Open, doi:10.3399/bjgpopen20X101069
］augustijns, Geusens, Verbeke, Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis［J］, Eur J Clin Pharmacol
］augustijns, Verbeke, Stereos elective Pharmacokinetic Properties of Chloroquine and De-Ethyl-Chloroquine in Humans［J］, clin pharmacokinet
］chattopadhyay, Mahajan, Kumar, Assessment of safety of the major antimalarial drugs ［J］, Expert Opin Drug Saf
］clemessy, Angel, Borron, Therapeutic trial of diazepam versus placebo in acute chloroquine intoxications of moderate gravity ［J］, Intensive Care Med
］de Wilde, Jochmans, Posthuma, Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture ［J］, Antimicrob Agents Chem
］fantini, Scala, Chahinian, Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection［J］, Int J Antimicrob Agents
］frisk-Holmberg, Bergqvist, Termond, The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects ［J］, Eur J Clin Pharmacol
］kaewkhao, Chotivanich, Winterberg, High sensitivity methods to quantify chloroquine and its metabolite in human blood samples using LC-MS/MS ［J］, Bioanalysis
］keyaerts, Vijgen, Maes, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine［J］, Biochem Biophys Res Commun
］looareesuwan, White, Chanthavanich, Cardiovascular toxicity and distribution kinetics of intravenous chloroquine ［J］, Br J Clin Pharmacol
］mullié, Jonet, Desgrouas, Differences in anti-malarial activity of 4-aminoalcohol quinoline enantiomers and investigation of the presumed underlying mechanism of action［J］, Malaria J
］murray, Down, Boulware, Reduction of Immune Activation with Chloroquine Therapy during Chronic HIV Infection ［J］, JVirol
］mzayek, Deng, Mather, Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers ［J］, PLoS Clin Trials
］ooi, Chew, Loh, In vitro inhibition of human influenza A virus replication by chloroquine［J］, J Virol
］parson, Koeniger, Johnson, Analysis of chloroquine and metabolites directly from whole-body animal tissue sections by liquid extraction surface analysis (LESA) and tandem mass spectrometry［J］, J Mass Spectrom
］salata, Calistri, Parolin, Antiviral activity of cationic amphiphilic drugs ［J］, Expert Rev Anti-infe
］thomé, Lopes, Tm, Chloroquine: Modes of action of an undervalued drug ［J］, Immunol Lett
］walker, Salako, Alvan, The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses ［J］, Brit J Clin Pharmaco
］中华人民共和国国家卫生与计划生育委员会, 抗疟药使用规范： WS/ T485-2016 ［S］